• Age: 18-75 years old (≥18, ≤75)

• Patients with newly diagnosed FIGO stage III or IV high-grade serous ovarian cancer, high-grade endometrioid carcinoma, primary peritoneal cancer, and/or fallopian tube cancer with high-risk factors for recurrence. High-risk recurrence is defined as follows:

‣ FIGO stage III with non-R0 resection;

⁃ FIGO stage IV;

⁃ Presence of ascites at initial diagnosis.

• Patients who have undergone primary debulking surgery (PDS) for ovarian cancer.

• ECOG performance status score: 0-2.

• Postoperative administration time ≤12 weeks.

• Expected survival of at least 3 months.

• Major organ function within 7 days prior to treatment meets the following criteria:

‣ Hemoglobin (HB) ≥90 g/L;

⁃ Absolute neutrophil count (ANC) ≥1.5×10⁹/L;

⁃ Platelets (PLT) ≥100×10⁹/L.

• Biochemical parameters must meet the following standards:

‣ Total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN);

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN, or ≤5×ULN if liver metastases are present;

⁃ Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr) ≥60 ml/min.

• Women of childbearing potential must use effective contraception.

⁃ Subjects must voluntarily join the study and sign the informed consent form (ICF).

⁃ Subjects are expected to have good compliance and the ability to follow up on efficacy and adverse reactions as required by the protocol.